| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/14/2005 | US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis |
| 07/14/2005 | US20050154045 E.g., N-[4-(2-Thienyl)phenyl]-1-azabicyclo[2.2.2]octane-3-carboxamide hydrochloride; treatment of impairments of perception, concentration, learning and/or memory |
| 07/14/2005 | US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 07/14/2005 | US20050154031 which are selective against serotonin 5-HT2A and 5-HT2C receptors; 2-amino-5-methyl-4-(naphth-1-yl)thiazole; irritable bowel syndrome, dyspepsia, gastroesophageal reflux, tachygastria; migraine, neurogenic pain, anxiety, depression, sleep disorder, asthma, incontinence, endometriosis, and fibrosis |
| 07/14/2005 | US20050154028 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazolidin-2-one; serotonin 5-ht2c receptor antagonist; antidepressant and anxiolytic agent |
| 07/14/2005 | US20050154026 Suitable for the treatment of gastric and intestinal disorders; in particular, omeprazole, rabeprazole, pantoprazole, esomeprazole |
| 07/14/2005 | US20050154025 6-[4-(fluoro- or trifluoromethyl)pyridyl-4-(p-fluorophenyl)-5-methylimidazol-2-yl] pyridones; cyclization of 1-phenyl-1-pyridyl-1,2-diaminopropanes with an acid, amidine, or nitrile compound; neuropeptide Y receptor antagonists; cardiovascular and central nervous system disorders, metabolic diseases |
| 07/14/2005 | US20050154023 1-(4-methoxynaphthalene-1-sulfonyl)-2,3-dihydro-1H-indole-3-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]amide; selective affinity for 5-HT6 receptor; psychosis, schizophrenia, depression, neurological disorders, cognitive enhancement, Parkinson's disease, ALS, Alzheimer's, Huntington's disease |
| 07/14/2005 | US20050154019 Substituted cyclic amine metalloprotease inhibitors |
| 07/14/2005 | US20050154018 Method for treating and preventing disorders using optically pure (+) norcisapride |
| 07/14/2005 | US20050154017 Novel azasugar derivative and drug containing the same as the active ingredient |
| 07/14/2005 | US20050154015 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050154013 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/14/2005 | US20050154012 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050154011 such as S)-3-Methylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, used in the treatment of protein tyrosine phosphatase (PTPase) mediated disorder such as diabetes |
| 07/14/2005 | US20050154004 4-Phenyl-6H-(1)Benzopyrano(4',3':4,5)pyrrolo(2,1-a)isoquinolin-6-one's and analogues, optionally mixed with acceptable carriers, excipients or diluents, used for treating multidrug resistant tumors, for inducing apoptosis and as immunology modulators |
| 07/14/2005 | US20050154003 Containing a 1H,3H-furo[3',4':6,7]indolizino[1,2-b]quinoline ring, e.g., {10-[(E)-(ter-butoxyimino)methyl]-3-ethyl-1,13-dioxo-11,13-dihydro-1H,3H-furo[3',4':6,7]indolizino[1,2-b]quinolin-3-yl}acetic acid; topoisomerase I inhibitors used to treat cancer |
| 07/14/2005 | US20050153996 Compounds that modulate ppar activity and methods for their preparation |
| 07/14/2005 | US20050153995 Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and methods for use thereof |
| 07/14/2005 | US20050153993 Treatment of statin side effects using uridine derivatives |
| 07/14/2005 | US20050153992 Glycogen synthase kinase-3 inhibitors; pyrrolo[3,2-d]pyrimidine: neurodegenerative diseases; antidiabetic, antiinflammatory, anticancer agents; 5-(2-aminoethyl)-6-(3-chloro(2-thienyl))-7-iodo-3-hydropyrrolo[3,2-d]pyrimidin-4-thione Trifluoroacetate; 4-halo intermediates |
| 07/14/2005 | US20050153987 Compounds |
| 07/14/2005 | US20050153983 Synergistic combination of an opioid analgesic and a nsaid |
| 07/14/2005 | US20050153980 Substituted indoles |
| 07/14/2005 | US20050153978 Medicaments |
| 07/14/2005 | US20050153977 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally |
| 07/14/2005 | US20050153974 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
| 07/14/2005 | US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes |
| 07/14/2005 | US20050153967 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form |
| 07/14/2005 | US20050153965 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 07/14/2005 | US20050153964 Novel compounds |
| 07/14/2005 | US20050153963 exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 |
| 07/14/2005 | US20050153960 Substituted arylamine derivatives and methods of use |
| 07/14/2005 | US20050153957 Beta2-adrenoceptor agonists |
| 07/14/2005 | US20050153949 Testosterone derivative |
| 07/14/2005 | US20050153930 Via gadolinium compounds as calcium channel blockers; drug screening |
| 07/14/2005 | US20050153920 Ribozymes used as prodrugs |
| 07/14/2005 | US20050153906 Such as Hurler syndrome and Batten by administering an aminoglycosidesuch as gentamicin, G418, hygromycin B, paromomycin, tobramycin, lividomycin A, amikacin, sisomycin, or neomycin, optionally in combination with an enzyme effective for enzyme replacement therapy, a polyionic compound or gene therapy |
| 07/14/2005 | US20050153901 Of EtO2C CH2 (R)Cgl-Aze-Pab-OH or its salt; high chemical and solid state stability; thrombin inhibitors |
| 07/14/2005 | US20050153892 Compound B as an angiogenic agent in combination with human growth factors |
| 07/14/2005 | US20050153890 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/14/2005 | US20050153889 Modulation of pericyte proliferation |
| 07/14/2005 | US20050153888 oligopeptides capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM), used for treatment of normal, degenerated and damaged NCAM presenting cells |
| 07/14/2005 | US20050153886 nucleotide sequences comprising cDNA and genomic DNA that code for angiogenesis factors, used for gene therapy |
| 07/14/2005 | US20050153884 Methods of therapy with thrombin derived peptides |
| 07/14/2005 | US20050153878 Fgfr agonists |
| 07/14/2005 | US20050153871 Administering N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016) to increase or prevent a decrease in cerebral blood flow |
| 07/14/2005 | US20050153445 System for expanding and differentiating human embryonic stem cells |
| 07/14/2005 | US20050153444 Using fibroblast growth factor to establish a line of embryonic stem cells |
| 07/14/2005 | US20050153372 Using calmodulin-dependent protein kinase and/or calcineurin as tool in detecting modulators of nervous system and brain disorders; enzyme inhibitors |
| 07/14/2005 | US20050152999 supercritically extracting an herb to obtain an oil extract and a residue;extracting the residue in a water/alcohol liquid mixture to obtain a post-supercritical hydroalcoholic extract; evaporating the water/alcohol liquid to form a powdered extract; mixing the powdered extract with the oil extract. |
| 07/14/2005 | US20050152930 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/14/2005 | US20050152913 Process for preapring maytansinol |
| 07/14/2005 | US20050152878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 07/14/2005 | US20050152870 Pharmaceutical composition which improves in vivo gene transfer |
| 07/14/2005 | US20050152846 Hydrofluoroalkane (HFA) propellant and co-solvents; inhalants; storage stability; deep lung penetration |
| 07/14/2005 | CA2550730A1 Method and compositions for identifying anti-hiv therapeutic compounds |
| 07/13/2005 | EP1553101A1 N-acetylglucosamine derivatives and use thereof |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553096A1 Pyrazole compounds |
| 07/13/2005 | EP1553094A1 Azulene derivatives and salts thereof |
| 07/13/2005 | EP1553091A1 Heteroaromatic pentacyclic compound and medicinal use thereof |
| 07/13/2005 | EP1553087A1 Preventive and/or therapeutic drugs for inflammatory intestinal diseases |
| 07/13/2005 | EP1553085A1 Cyclic amine derivatives and their use as drugs |
| 07/13/2005 | EP1553084A1 Piperidine derivative, process for producing the same, and use |
| 07/13/2005 | EP1553074A1 Fused benzene derivative and use |
| 07/13/2005 | EP1552852A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 07/13/2005 | EP1552849A1 Immunotherapeutic for cancer |
| 07/13/2005 | EP1552847A1 Inhibitors for continuous activation of calcineurin |
| 07/13/2005 | EP1552846A2 Use of heparinases to decrease inflammatory responses |
| 07/13/2005 | EP1552845A1 Preventives/remedies for cancer |
| 07/13/2005 | EP1552843A1 Dioxin elimination promoter |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552838A1 Rubrofusarin glycoside-containing composition |
| 07/13/2005 | EP1552837A1 Antipsoriatic agent |
| 07/13/2005 | EP1552834A1 Neurotrophic factor production promoter |
| 07/13/2005 | EP1552832A1 Process for producing coated preparation |
| 07/13/2005 | EP1552830A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 07/13/2005 | EP1552828A1 Thrombopoetin receptor activator and process for producing the same |
| 07/13/2005 | EP1552826A1 Amino acid compositions for improving central functions |
| 07/13/2005 | EP1552825A1 Therapeutic agent for overactive bladder |
| 07/13/2005 | EP1552824A1 Therapeutic agent for chronic obstructive pulmonary disease |
| 07/13/2005 | EP1552745A1 Therapeutic combinations of venous dilators and arterial dilators |
| 07/13/2005 | EP1552002A2 Aptamer-toxin molecules and methods for using same |
| 07/13/2005 | EP1551990A2 Diagnosis and treatment of chemoresistant tumors |
| 07/13/2005 | EP1551964A2 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 07/13/2005 | EP1551962A2 Mitotic kinesin binding site |
| 07/13/2005 | EP1551955A2 Methods of implanting mesenchymal stem cells for tissue repair and formation |
| 07/13/2005 | EP1551877A2 Taci antibodies and uses thereof |
| 07/13/2005 | EP1551872A2 G-protein coupled receptors |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551860A1 Glucocorticoid receptor ligands for the treatment of metabolic disorders |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551844A2 Antitumoral analogs of lamellarins |
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551840A1 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551834A1 Substituted quinazolinone compounds |
| 07/13/2005 | EP1551830A2 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibators |
| 07/13/2005 | EP1551826A1 Hydantoine derivatives and their use as tace inhibitors |